Trial Profile
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Pulmonary sarcoidosis; Sarcoidosis
- Focus Therapeutic Use
- 20 Jul 2023 Results assessing safety and efficacy of the sarilumab, in subjects with glucocorticoid-dependent sarcoidosis, published in the Rheumatology.
- 23 Feb 2023 Status changed from active, no longer recruiting to completed.
- 12 Jan 2022 Status changed from recruiting to active, no longer recruiting.